Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1

Molecular and Cellular Biology

Volumn 25, Issue 13, 2005, Pages 5404-5416

  Shetty, Shashirekha ^a   Graham, Bonnie A ^a   Brown, Jennifer G ^a   Hu, Xiaojie ^a   Vegh Yarema, Nicolette ^a   Harding, Gary ^a   Paul, James T ^a   Gibson, Spencer B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 5; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER THERAPY; CONTROLLED STUDY; DR5 GENE; ENZYME REGULATION; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INTRON; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; STIMULUS RESPONSE;

APOPTOSIS; BINDING SITES; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; EPIDERMAL GROWTH FACTOR; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION; GENES, REPORTER; HISTONE DEACETYLASES; HUMANS; INTRONS; KIDNEY; LUCIFERASES; MUTATION; NF-KAPPA B; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 20744433491     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.13.5404-5416.2005     Document Type: Article

References (62)

1. Aron, J. L., M. R. Parthun, G. Marcucci, S. Kitada, A. P. Mone, M. E. Davis, T. Shen, T. Murphy, J. Wickham, C. Kanakry, D. M. Lucas, J. C. Reed, M. R. Grever, and J. C. Byrd. 2003. Depsipeptide (FR901228) induces histone acctylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 102:652-658.
2. Ashburner, B. P., S. D. Westerheide, and A. S. Baldwin, Jr. 2001. The p65 (RelA) suhunit of NF-κB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell. Biol. 21:7065-7077.
3. Ashkenazi, A., and V. M. Dixit. 1998. Death receptors: signaling and modulation. Science 281:1305-1308.
4. Baldwin, A. S. 2001. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J. Clin. Investig. 107:241-246.
5. Baldwin, A. S., Jr. 1996. The NF-κB and IκB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649-683.
6. Bodmer, J. L., N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis, and J. Tschopp. 2000. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:241-243.
7. Campbell, K. J., S. Rocha, and N. D. Perkins. 2004. Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol. Cell 13:853-865.
8. Chen, X., K. Kandasamy, and R. K. Srivastava. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor κB in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res. 63:1059-1066.
9. Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-κB puzzle. Cell 109(Suppl.):S81-S96.
10. Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225-260.
11. Gibson, S. B., R. Oyer, A. C. Spalding, S. M. Anderson, and G. L. Johnson. 2000. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell. Biol. 20:205-212.
12. Gray, S. G., and B. T. Teh. 2001. Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr. Mol. Med. 1:401-429.
13. Gregory, P. D., K. Wagner, and W. Horz. 2001. Histone acetylation and chromatin remodeling. Exp. Cell Res. 265:195-202.
14. Griffith, T. S., W. A. Chin, G. C. Jackson, D. H. Lynch, and M. Z. Kubin. 1998. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:2833-2840.
15. Grimm, S., M. K. Bauer, P. A. Baeuerle, and K. Schulze-Osthoff. 1996. Bel-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J. Cell Biol. 134:13-23.
16. Henson, E. S., E. M. Gibson, J. Villanueva, N. A. Bristow, N. Haney, and S. B. Gibson. 2003. Increased expression of Mcl-1 is responsible for the blockage of TRAIL-induced apoptosis mediated by EGF/ErbB1 signaling pathway. J. Cell. Biochem. 89:1177-1192.
17. Higuchi, H., A. Grambihler, A. Canbay, S. F. Bronk, and G. J. Gores. 2004. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 279:51-60.
18. Hockenbery, D. M., Z. N. Oltvai, X. M. Yin, C. L. Milliman, and S. J. Korsmeyer. 1993. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251.
19. Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu, T. Ohtsuka, H. Zhang, J. D. Mountz, W. J. Koopman, R. P. Kimberly, and T. Zhou. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7:954-960.
20. Johnston, J. B., A. F. Kabore, J. Strutinsky, X. Hu, J. T. Paul, D. M. Kropp, B. Kuschak, A. Begleiter, and S. B. Gibson. 2003. Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 22:8356-8369.
21. Keane, M. M., S. A. Ettenberg, M. M. Nau, E. K. Russell, and S. Lipkowitz. 1999. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59:734-741.
22. Kramer, O. H., M. Gottlicher, and T. Heinzel. 2001. Histone deacetylase as a therapeutic target. Trends Endocrinol. Metab. 12:294-300.
23. Kreuz, S., D. Siegmund, P. Scheurich, and H. Wajant. 2001. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21:3964-3973.
24. Mahlknecht, U., and D. Hoelzer. 2000. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol. Med. 6:623-644.
25. Marks, P., R. A. Rifkind, V. M. Richon, R. Breslow, T. Miller, and W. K. Kelly. 2001. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1:194-202.
26. Marks, P. A., V. M. Richon, R. Breslow, and R. A. Rifkind. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13:477-483.
27. Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Rogers-Graham, S. W. Lowe, C. J. Der, and A. S. Baldwin, Jr. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278:1812-1815.
28. Meng, R. D., E. R. McDonald III, M. S. Sheikh, A. J. Fornace, Jr., and W. S. El-Deiry. 2000. The TRAIL decoy receptor TRUNDD (DcR2, TRA1L-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol. Ther. 1:130-144.
29. Nakata, S., T. Yoshida, M. Horinaka, T. Shiraishi, M. Wakada, and T. Sakai. 2004. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23:6261-6271.
30. Nebbioso, A., N. Clarke, E. Voltz, E. Germain, C. Ambrosino, P. Bontempo, R. Alvarez, E. M. Schiavone, F. Ferrara, F. Bresciani, A. Weisz, A. R. de Lera, H. Gronemeyer, and L. Altucci. 2005. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11:77-84.
31. Obeid, L. M., C. M. Linardic, L. A. Karolak, and Y. A. Hannun. 1993. Programmed cell death induced by ceramide. Science 259:1769-1771.
32. Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336-2340.
33. Pan, G., K. O'Rourke, A. M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni, and V. M. Dixit. 1997. The receptor for the cytotoxic ligand TRAIL. Science 276:111-113.
34. Ravi, R., G. C. Bedi, L. W. Engstrom, Q. Zeng, B. Mookerjee, C. Gelinas, E. J. Fuchs, and A. Bedi. 2001. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat. Cell Biol. 3:409-416.
35. Rosato, R. R., J. A. Almenara, Y. Dai, and S. Grant. 2003. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2:1273-1284.
36. Ryan, K. M., M. K. Ernst, N. R. Rice, and K. H. Vousden. 2000. Role of NF-κB in p53-mediated programmed cell death. Nature 404:892-897.
37. Schreck, R., P. Rieber, and P. A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:2247-2258.
38. Schulze-Osthoff, K., D. Ferrari, M. Los, S. Wesselborg, and M. E. Peter. 1998. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:439-459.
39. Schutze, S., K. Potthoff, T. Machleidt, D. Berkovic, K. Wiegmann, and M. Kranke. 1992. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 71:765-776.
40. Screaton, G. R., J. Mongkolsapaya, X. N. Xu, A. E. Cowper, A. J. McMichael, and J. I. Bell. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693-696.
41. Sheridan, J. P., S. A. Marsters, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, and A. Ashkenazi. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
42. Shetty, S., J. B. Gladden, E. S. Henson, X. Hu, J. Villanueva, N. Haney, and S. B. Gibson. 2002. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFκB activation in epithelial derived cell lines. Apoptosis 7:413-420.
43. Singh, T. R., S. Shankar, X. Chen, M. Asim, and R. K. Srivastava. 2003. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63:5390-5400.
44. 43a.Spencer, V. A., J. M. Sun, L. Li, and J. R. Davie. 2003. Chromatin immunoprecipitation: a tool for studying histone acetylation and transcription factor binding. Methods 31:67-75.
45. Srivastava, R. K. 2001. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3:535-546.
46. Strahl, B. D., and C. D. Allis. 2000. The language of covalent histone modifications. Nature 403:41-45.
47. Suliman, A., A. Lam, R. Datta, and R. K. Srivastava. 2001. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 20:2122-2133.
48. Takimoto, R., and W. S. El-Deiry. 2000. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 19:1735-1743.
49. Tergaonkar, V., M. Pando, O. Vafa, G. Wahl, and I. Verma. 2002. p53 stabilization is decreased upon NFκB activation: a role for NFκB in acquisition of resistance to chemotherapy. Cancer Cell 1:493-503.
50. Timmermann, S., H. Lehrmann, A. Polesskaya, and A. Harel-Bellan. 2001. Histone acetylation and disease. Cell. Mol. Life Sci. 58:728-736.
51. Urnov, F. D., E. J. Rebar, A. Reik, and P. P. Pandolfi. 2002. Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics. EMBO Rep. 3:610-615.
52. Wadgaonkar, R., K. M. Phelps, Z. Haque, A. J. Williams, E. S. Silverman, and T. Collins. 1999. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J. Biol. Chem. 274:1879-1882.
53. Walczak, H., M. A. Degli-Esposti, R. S. Johnson, P. J. Smolak, J. Y. Waugh, N. Boiani, M. S. Timour, M. J. Gerhart, K. A. Schooley, C. A. Smith, R. G. Goodwin, and C. T. Rauch. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:5386-5397.
54. Walczak, H., R. E. Miller, K. Ariail, B. Gliniak, T. S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R. G. Goodwin, C. T. Rauch, J. C. Schuh, and D. H. Lynch. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
55. Wang, C. Y., M. W. Mayo, R. G. Korneluk, D. V. Goeddel, and A. S. Baldwin, Jr. 1998. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 281:1680-1683.
56. Wang, S., and W. S. El-Deiry. 2004. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res. 64:6666-6672.
57. Webster, G. A., and N. D. Perkins. 1999. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19:3485-3495.
58. Wu, G. S., T. F. Burns, E. R. McDonald III, W. Jiang, R. Meng, I. D. Krantz, G. Kao, D. D. Gan, J. Y. Zhou, R. Muschel, S. R. Hamilton, N. B. Spinner, S. Markowitz, G. Wu, and W. S. el-Deiry. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet 17:141-143.
59. Wu, M. X., Z. Ao, K. V. Prasad, R. Wu, and S. F. Schlossman. 1998. IEX-IL, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 281:998-1001.
60. Yoshida, T., A. Maeda, N. Tani, and T. Sakai. 2001. Promoter structure and transcription initiation sites of the human death receptor 5ATRAIL-R2 gene. FEBS Lett. 507:381-385.
61. Zhao, H., L. L. Hart, U. Keller, L. T. Holth, and J. R. Davie. 2002. Characterization of stably transfected fusion protein GFP-estrogen receptor-alpha in MCF-7 human breast cancer cells. J. Cell. Biochem. 86:365-375.
62. Zhong, H., M. J. May, E. Jimi, and S. Ghosh. 2002. The phosphorylation status of nuclear NF-κ B determines its association with CBP/p300 or HDAC-1. Mol. Cell 9:625-636.